利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

71 条记录 (耗时 0.023 秒)

    PEPTIDES FOR TREATMENT OF AUTOIMMUNE DISEASES
    51.
    发明公开
    PEPTIDES FOR TREATMENT OF AUTOIMMUNE DISEASES 有权
    肽自身免疫性疾病的治疗

    公开(公告)号：EP1709070A1

    公开(公告)日：2006-10-11

    申请号：EP05701998.6

    申请日：2005-01-24

    申请人： KINGS COLLEGE LONDON

    发明人： PEAKMAN, Mark

    IPC分类号： C07K14/47 ,  A61K39/00 ,  C07K14/62

    CPC分类号： C07K14/4713 ,  A61K38/00 ,  C07K14/62

    摘要： Peptides for use in the therapy or prevention of Type 1 Diabetes mellitus (TIDM) are those having sequences containing QPLALEGSLQK (SEQ ID NO: 9). j Examples are those having a sequence selected from the group consisting 10 essentially of GGGPGAGSLQPLALEGSLQK (SEQ ID NO: 4), GSLQPLALEGSLQKRGIV (SEQ ID NO: 5), and QPLALEGSLQKRGIVEQ (SEQ ID NO: 6). One or more of the above peptides may be combined with one or more peptides having a sequence or sequences consisting essentially of sequences selected from LAKEWQALCAYQAEPNTCATAQGI?GNIK (SEQ ID NO: 11), KLKVESSPSRSDYINASPIIEHDP (SEQ ID NO: 12), and SFYLKNVQTQETRTLTQFHF (SEQ ID NO: 13). Also disclosed is a method of assessing the potential of a peptide for TIDM therapy or prevention which comprises subjecting the candidate peptide to a frst assay indicative of a pathogenic T cell response in blood or other biological sample, such as an ELISPOT assay for IFN-y. In the case of a positive response to the first assay, the candidate peptide is subjected to a second assay indicative of a regulatory T cell response to the peptide, such as an ELISPOT assay for IL­ 10).

    DUAL DIRECTION CHANNEL ESTIMATOR
    53.
    发明公开
    DUAL DIRECTION CHANNEL ESTIMATOR 审中-公开
    CHANNEL预测双向

    公开(公告)号：EP1080567A1

    公开(公告)日：2001-03-07

    申请号：EP99922361.3

    申请日：1999-05-19

    申请人： KINGS COLLEGE LONDON

    发明人： WU, Jianjun ,  AGHVAMI, Abdol, Hamid

    IPC分类号： H04L25/02 ,  H04B7/005

    CPC分类号： H04L25/0212 ,  H04L25/0228

    摘要： In the Global System for Mobil Communication (GSM) an improvement in estimating the channel impulse response (CIR) is obtained by starting up two channel estimators using the midamble and obtaining channel estimations with split burst, the two estimations are then cross-correlated to obtain the estimated CIR.

    AUTOMATIC MULTIPLE CELL SCREENING MEANS
    54.
    发明公开
    AUTOMATIC MULTIPLE CELL SCREENING MEANS 失效
    自动装置测试多个细胞

    公开(公告)号：EP0927347A1

    公开(公告)日：1999-07-07

    申请号：EP97940245.0

    申请日：1997-09-15

    申请人： KINGS COLLEGE LONDON

    发明人： ZHANG, Wu ,  KOH, Carolyn, Ann ,  SAVIDGE, Jeffrey

    IPC分类号： G01N21

    CPC分类号： G01N21/17 ,  G01N21/251

    摘要： Apparatus and a method for measuring and comparing the optical properties of liquids, particularly liquids containing a solid, in which the liquids are held in a series of containers (2) held in a holding means (3) in a carousel (1); the carousel is rotated so the containers sequentially pass through a beam of light from a laser (9) with the light passing through each liquid preferably via a quarter wave plate (12) and then a beam splitter (14) which splits the light into two orthogonally polarised beams of light which are passed to a photodetector (15, 16). By measring and comparing the properties of each beam of light the properties of the liquid can be measured. The method is particularly useful for continuously measuring clathrate formation in a clathrate forming system in the container; the properties which can be measured are the transmission, birefringence and viscosity, by having a magnetic stirrer (22) and detecting the rate of stirring changes in the viscosity can be measured.

    PBD ANTIBACTERIAL AGENTS
    59.
    发明公开
    PBD ANTIBACTERIAL AGENTS 审中-公开

    公开(公告)号：EP3386985A1

    公开(公告)日：2018-10-17

    申请号：EP16813021.9

    申请日：2016-12-09

    申请人： Kings College London ,  The Secretary of State for Health

    发明人： RAHMAN, Khondaker Mirazur ,  SUTTON, John Mark ,  PICCONI, Pietro

    IPC分类号： C07D487/04 ,  A61K31/5517 ,  A61P31/04

    CPC分类号： C07D487/04 ,  A61K31/5517 ,  A61K45/06 ,  A61P31/04

    摘要： The invention relates to pyrrolobenzodiazepines compounds (PBDs) and to pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular, to treat bacterial infections. The PBDs are compounds of formula (I): and salts and solvates thereof; wherein: dotted lines indicates the optional presence of a double bond; X, X1, X2, X3 and X4 are connecting functional groups; L is C1-12 alkylene; R4, R5 and R6 are independently selected from phenylene, cyclopentanylene, cyclohexanylene, 5 - to 9 -membered heteroarylene and 5 - to 6-membered hetereocyclylene groups, and these groups are optionally substituted with up to three optional substituent groups; R7 is selected from N(C1- 6 alkyl)(C1-6alkyl), 5 - to 6-membered nitrogen-containing hetereocyclyl groups, a monosaccharide moiety and an amino monosaccharide moiety wherein these groups are optionally substituted; and R8 and R9 either together form a double bond, or are selected from H and OR14, or R8 is a prodrug moiety and R9 is OR14; m is 0 or 1; with the proviso that when X4 is C(O)NH then the up to three optional substituents of R7 are not selected from (CH2)k -CO2R12; with the proviso that when X4 is (CH2)tO then R4 is not phenylene, m is 1 and R6 is not a 5 - to 9 -membered heteroarylene; and with the proviso that when X4 is C(O)NH or NHC(O) that R4 and/or R6 is not 5 - to 9 -membered heteroarylene.

    MULTI-PEPTIDE COMPOSITION
    60.
    发明公开
    MULTI-PEPTIDE COMPOSITION 审中-公开
    多肽组合物

    公开(公告)号：EP3307298A1

    公开(公告)日：2018-04-18

    申请号：EP16729347.1

    申请日：2016-06-10

    申请人： Kings College London

    发明人： PEAKMAN, Mark

    IPC分类号： A61K38/10 ,  A61K38/16 ,  A61K38/28 ,  A61P3/10 ,  G01N33/68

    摘要： The invention relates to a specific peptide combination. The peptide combination may be present in a pharmaceutically acceptable composition. The peptide combination can be used in the therapy or prevention of Type 1 Diabetes (TID). The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the specific peptide combination.